Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation by Barbier Torres, Lucía et al.
ARTICLE
Silencing hepatic MCJ attenuates non-alcoholic
fatty liver disease (NAFLD) by increasing
mitochondrial fatty acid oxidation
Lucía Barbier-Torres1,10, Karen A. Fortner2,10, Paula Iruzubieta3, Teresa C. Delgado1, Emily Giddings2,
Youdinghuan Chen 4, Devin Champagne 2, David Fernández-Ramos1, Daniela Mestre5,
Beatriz Gomez-Santos5, Marta Varela-Rey1, Virginia Gutiérrez de Juan1, Pablo Fernández-Tussy1,
Imanol Zubiete-Franco1, Carmelo García-Monzón6, Águeda González-Rodríguez6, Dhaval Oza7,
Felipe Valença-Pereira8, Qian Fang8, Javier Crespo3, Patricia Aspichueta5, Frederic Tremblay7,
Brock C. Christensen 4, Juan Anguita 9, María Luz Martínez-Chantar 1,11 & Mercedes Rincón 2,8,11✉
Nonalcoholic fatty liver disease (NAFLD) is considered the next major health epidemic with
an estimated 25% worldwide prevalence. No drugs have yet been approved and NAFLD
remains a major unmet need. Here, we identify MCJ (Methylation-Controlled J protein) as a
target for non-alcoholic steatohepatitis (NASH), an advanced phase of NAFLD. MCJ is an
endogenous negative regulator of the respiratory chain Complex I that acts to restrain
mitochondrial respiration. We show that therapeutic targeting of MCJ in the liver with
nanoparticle- and GalNAc-formulated siRNA efficiently reduces liver lipid accumulation and
fibrosis in multiple NASH mouse models. Decreasing MCJ expression enhances the capacity
of hepatocytes to mediate β-oxidation of fatty acids and minimizes lipid accumulation, which
results in reduced hepatocyte damage and fibrosis. Moreover, MCJ levels in the liver of
NAFLD patients are elevated relative to healthy subjects. Thus, inhibition of MCJ emerges as
an alternative approach to treat NAFLD.
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Nonalcoholic fatty liver disease (NAFLD) is considered amajor health epidemic1,2. The highest prevalence ofNAFLD is found in populations with obesity or type 2
diabetes, but NAFLD is also frequently found in otherwise heal-
thy people without obvious risk factors1,2. NAFLD includes a
wide spectrum of different pathological conditions3,4. While
simple symptomatic steatosis (accumulation of lipids in hepato-
cytes) is the earliest stage of NAFLD, it can progress to non-
alcoholic steatohepatitis (NASH), characterized by the presence
of fibrosis in the liver3,4. NASH is currently the most common
cause of chronic liver disease. Patients with NASH have increased
liver-mediated mortality and an increased risk of developing
cardiovascular diseases. A fraction of NASH patients develops
cirrhosis due to progressive liver fibrosis.
NAFLD is initiated by the excessive accumulation of lipids in
the liver due to an increased delivery of fatty acids from adipose
tissue accompanied by an imbalance between lipid degradation
and de novo lipid synthesis1,2. The accumulation of lipids within
hepatocytes triggers a chronic inflammatory response that
involves other hepatic cell types, such as Kupffer and stellate cells,
and can lead to liver fibrosis (NASH). Fatty acids are catabolized
in the liver by β-oxidation within mitochondria, with the
resulting reducing products (NADH and FADH2) being fed into
the mitochondrial electron transport chain (ETC). Lipid catabo-
lism in the liver is therefore highly dependent on mitochondrial
metabolism. Increasing mitochondrial respiratory activity in the
liver could enhance degradation of fatty acids, thereby preventing
their accumulation and liver disease progression. However, this
pathway has not been extensively considered therapeutically for
the treatment of NAFLD because of the potential increase in the
generation of reactive oxygen species (ROS) as a result of
enhanced β-oxidation.
MCJ is a transmembrane protein in the inner mitochondrial
membrane (encoded by the Dnajc15 nuclear gene) that acts as an
endogenous negative regulator of Complex I and restrains
mitochondrial respiration5. Loss of MCJ leads to increased
Complex I activity, mitochondrial membrane potential, and
mitochondrial respiration5–7. However, loss of MCJ does not
increase the production of ROS because it also promotes
the formation of respiratory supercomplexes that are commonly
formed by Complex I, III, and IV of the ETC5–7. The major
function of supercomplexes is to facilitate the transport of elec-
trons between Complex I to III and III to IV by bringing them
into proximity, and thereby minimize electron leak8,9. MCJ is
expressed predominantly in highly metabolic tissues including the
liver, heart, and kidney5. Under normal physiological conditions
MCJ is dispensable as no obvious abnormalities can be found in
MCJ-deficient mice5. Disrupting MCJ expression and/or function
in the liver could, therefore, be a safe strategy to minimize lipid
accumulation and the development of fibrosis, and thereby treat
NASH. In this study we show that MCJ-deficient mice are
resistant to the development of fatty liver and NASH. Impor-
tantly, using siRNA as a therapeutic approach we show that
treatment with different formulations of siMCJ after the onset of
the disease reduces liver steatosis and fibrosis in multiple mouse
models. These results, together with the increased levels of MCJ
in liver of NAFLD patients we report here, suggest that MCJ is
emerging as an alternative target for treatment of NASH.
Results
Reduced NAFLD liver steatosis and fibrosis in MCJ deficient
mice. MCJ is a negative regulator of respiratory Complex I and
mitochondrial respiration5–7. MCJ is expressed in the liver5–7,
markedly at higher levels in hepatocytes than in other liver
resident cells such as Kupffer cells and stellate cells
(Supplementary Fig. 1). We therefore investigated the role of MCJ
in fatty liver disease using MCJ-deficient (MCJ KO) mice and the
methionine- and choline-deficient (MCD) diet mouse model of
NASH where lipid accumulation in the liver causes steatosis
followed by fibrosis. WT and MCJ KO mice were maintained for
2 weeks on the MCD diet. Histological analysis of the liver
showed profound steatosis in WT mice, but minimal steatosis was
found in MCJ KO mice (Fig. 1a). The analysis of lipid accumu-
lation showed reduced accumulation of lipids in the livers of MCJ
KO mice relative to WT mice (Fig. 1b, c). Protection from lipid-
mediated liver damage in MCJ KO mice was further demon-
strated by the lower levels of serum aspartate aminotransferase
(Fig. 1d). To examine whether loss of MCJ could also impact liver
fibrosis, WT and MCJ KO mice were maintained on the MCD
diet for 3 weeks. Liver fibrosis was determined by Picro Sirius Red
staining of liver sections. Similar to liver steatosis, MCJ KO mice
developed less fibrosis in the liver relative to WT mice (Fig. 1e, f).
Thus, systemic loss of MCJ protects mice from developing NASH.
Decreased MCJ gene methylation and increased expression in
human NAFLD. DNAJC15 has been recently identified as one of
the genes differentially expressed in humans in association with
metabolic disorders10,11. No studies to date have investigated
MCJ/DNAJC15 in NAFLD patients. We therefore examined MCJ
protein levels by immunohistochemistry using a specific anti-
MCJ monoclonal antibody12 in liver biopsies from a cohort of
patients with biopsy-proven NAFLD as well as from a cohort of
healthy subjects. Increased MCJ levels were found in livers from
NAFLD patients compared with healthy controls (Fig. 2a, b),
supporting a role of MCJ in NAFLD.
The expression of MCJ is known to be downregulated by gene
promoter DNA methylation in different types of cancer cells13–15.
However, it is unclear whether regulation of DNAJC15 expression
by DNA methylation occurs in nontumor liver tissues. We have
recently identified three CpG sites (cg14729962, cg09677945,
cg15988970) within the proximal promoter of human DNAJC15
where methylation inversely correlates with expression in human
breast cancer15. Here, we integrated and analyzed DNAJC15 DNA
methylation data in healthy liver tissues from six independent
Gene Expression Omnibus (GEO) data sets and The Cancer
Genome Atlas (TCGA), and observed the highest variability in
methylation of these three CpG sites relative to the other CpG
sites (Supplementary Fig. 2a, b). Consistent with our published
results in breast tissues15, methylation of the three DNAJC15 CpG
sites was inversely correlated with gene expression in normal
TCGA liver tissues, where lower DNA methylation was associated
with higher levels of DNAJC15 transcripts all Pearson Corr. <
−0.5 and P < 0.001, (Fig. 2c). We then compared the DNAJC15
methylation profile of these three sites in livers from healthy (n=
106) and NAFLD patients (n= 87) in the six GEO data sets.
These three DNAJC15 promoter CpGs were hypomethylated in
NAFLD patient livers relative to healthy livers at the three CpG
sites related to DNAJC15 expression (all Wilcoxon’s test P < 0.01,
Fig. 2d). Thus, consistent with the increased levels of MCJ protein
expression in liver of NAFLD patients, these results further
support the association of liver MCJ levels and human NAFLD.
LNP-siMCJ treatment reduces liver steatosis and fibrosis in
MCD diet models. The results above suggested that MCJ could
be a potential target for NAFLD. We investigated whether MCJ
could be therapeutically targeted in the liver as an approach to
treat NASH. siRNA successfully attenuates the expression of liver
proteins, and the first siRNA therapies were recently approved by
FDA for a rare liver disease16,17. We followed the same approach
to target MCJ in the liver using a siRNA specific for mouse
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Dnajc15 (siMCJ) previously validated as a shRNA plasmid18. To
determine the efficacy of siMCJ in reducing MCJ expression
in vivo, WT mice were i.v. administered a single dose of siMCJ
using Invivofectamine (lipid-based) as a delivery system that
resembles the lipid nanoparticles (LNP) delivery system used for
one of the FDA-approved siRNA-based therapies. Livers were
harvested at different time points after siMCJ administration and
levels of MCJ were examined by Western blot analysis. As early as
24 h after the administration of siMCJ, endogenous MCJ was
almost undetectable in the liver (Fig. 3a). The levels of MCJ
remained low for up to 7 days following siMCJ administration
(Fig. 3a). No effect on MCJ levels was observed when a control
siRNA was administered (Supplementary Fig. 3a). In contrast to
MCJ in liver, siMCJ treatment did not obviously affect MCJ levels
in the heart or kidneys (Supplementary Fig. 3b), two other tissues
where MCJ is highly expressed5. Thus, siMCJ administration was
highly efficient in reducing the levels of MCJ in the liver. To
address potential toxicity of the siMCJ treatment, mice were
administered a dose fivefold higher than the experimental dose
and markers of toxicity were examined 1 week later. Serum levels
of transaminases, albumin (liver dysfunction), and urea (renal
toxicity) were not elevated in mice that received high doses of
siMCJ compared with control mice (Supplementary Fig. 4a, b, c).
We therefore investigated the effect of siMCJ administration as
therapy in mouse models of fatty liver disease. We first tested
acute fasting as a model of early phase NAFLD because mice
develop liver steatosis with a marked lipid accumulation due to
the rapid and overwhelming hydrolysis of lipids in the adipose
tissue. We have previously shown that MCJ deficiency prevents
acute lipid accumulation in the liver during fasting5. WT mice
were given a single i.v. dose of siMCJ 18 h prior to food
withdrawal, and mice were euthanized after 36 h of fasting.
Analysis of MCJ in the liver by Western blot analysis showed a
clear reduction (Supplementary Fig. 5a). While control mice
showed a massive accumulation of lipids in the liver, minimal
lipids could be found in siMCJ-treated mice (Supplementary
Fig. 5b, c). Thus, targeting MCJ in the liver by administering
siMCJ is an effective way to reduce lipid accumulation.
We then assessed whether the administration of siMCJ could
prevent the accumulation of lipids in the liver and development
of NASH using the MCD diet model. Based on the pharmaco-
dynamics shown above, a weekly i.v. dose of siMCJ was chosen
starting simultaneously with the MCD diet. As controls, mice
received either no siRNA (control) or a non-specific siRNA
control (siRNAc). Mice were analyzed after 3 weeks on MCD diet
(1 week after the last siMCJ treatment). The levels of MCJ
remained low in siMCJ treated mice compared with control
animals even 1 week after the last treatment (Supplementary
Fig. 6a). Relative to the livers of control and control-siRNA
treated mice, only minor liver steatosis was present in the livers of
siMCJ-treated mice, as determined by H&E staining (Fig. 3b), and
lipid staining of liver sections (Supplementary Fig. 6b). Thus,
inhibition of MCJ expression in the liver is an efficient approach
to prevent progressive lipid accumulation. Analysis of liver
fibrosis by Picro Sirius Red staining revealed markedly reduced


























































Fig. 1 MCJ deficient mice are resistant to develop liver steatosis and fibrosis in the MCD diet model. (a–d) WT (n= 5) and MCJ KO (n= 5) mice were
placed on MCD (methionine- and choline-deficient) diet for 2 weeks prior to liver harvest. a Representative liver H&E images from WT and MCJ KO mice.
b Representative images and (c) quantitation of liver lipid content determined by Sudan III staining and shown as percentage of the total histological area.
(d) Serum AST levels. e, f WT (n= 5) and MCJ KO (n= 5) mice were placed on MCD diet for 3 weeks prior to liver harvest. e Representative images
and (f) quantification of liver fibrosis determined by Picro Sirius Red staining and shown as the number of fibrotic areas per histological section. *denotes
p < 0.05 as determined by Student´s t test. Error bars show standard error (SE) in (c) and (d), and standard deviation (SD) in (f). Source data are provided
as a Source Data file.
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Fig. 6c). Thus, administration of siMCJ simultaneously with
MCD diet prevents the development of NASH in mice.
To examine the therapeutic value of siMCJ after the onset of
the disease, we used a modified MCD diet (mMCD diet) that is
fully deficient in choline but contains a small amount (0.1%) of
methionine. Mice can be maintained on this diet for 4 weeks or
longer with no substantial weight loss19. siMCJ treatment was
initiated one week after starting the diet, when the mice already
displayed very high liver lipid content (Fig. 3d), mild inflamma-
tion (Fig. 3e), and signs of fibrosis (Fig. 3f, g). The mice were
maintained on mMCD diet for an additional 3 weeks with a
weekly dose of siMCJ and euthanized 1 week after the last dose
(4 weeks on diet total). The efficient suppression of MCJ
expression in the liver was confirmed by Western blot analysis
(Supplementary Fig. 7a). Analysis of H&E staining of liver
sections showed minimal levels of steatosis in siMCJ-treated mice
relative to controls (Supplementary Fig. 7b). In addition,
histochemical staining analysis revealed low lipid content in the
livers of siMCJ-treated mice compared with nontreated mice and
mice fed mMCD diet for only 1 week (Fig. 3d and Supplementary
Fig. 7c). Thus, treatment with siMCJ after the onset of liver
steatosis and development of fatty liver reduces the lipid content
of the liver. While enhanced β-oxidation and mitochondrial ETC
activity may lead to increase ROS production due to electron leak,
we have shown that loss of MCJ increases Complex I activity and
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Fig. 2 Increased MCJ expression in the liver correlates with the development of NAFLD in humans. a Quantification and (b) representative images of
liver MCJ expression determined by immunohistochemistry in human samples from healthy control subjects (Normal) (n= 5) and patients with non-
alcoholic fatty liver disease (NAFLD) (n= 21). *denotes p < 0.05 as determined by Student’s t test. Error bars show standard error (SE). c Linear regression
analysis for the methylation beta scores and DNAJC15 mRNA levels of the 3 CpG sites identified in Supplementary Fig 2a, b. Results show a strong negative
association (all Pearson correlation coefficients <−0.50 and linear regression P < 0.001). d Wilcoxon’s rank-sum test comparing methylation levels
in NAFLD patients and healthy human liver at three gene-expression-related CpG within the DnaJC15 promoter, based on six independent GEO data sets.
**P < 0.01, ***P < 0.001. Error bars show standard error (SE) in (a). Source data are provided as a Source Data file.
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Fig. 3 Reducing MCJ levels in the liver by in vivo administration of siMCJ decreases liver steatosis and fibrosis in the MCD diet models. a WT mice
received a single i.v. dose (1.7 mg/Kg) of siMCJ using Invivofectamine as a delivery system. Livers were harvested at the times indicated and MCJ levels
were examined by Western blot analysis. b and c WT mice were placed on MCD diet and received an i.v. administration of Invivofectamine-formulated
siMCJ (n= 5), Invivofectamine-formulated nonspecific control siRNA (siRNAc) (n= 3), or PBS (n= 5) weekly starting at the initiation of the diet. Mice
were harvested after 3 weeks on MCD diet (1 week after the last dose of siMCJ). b Representative images of liver lipids by H&E staining of liver sections
are shown. c Number of fibrotic areas per histological section of the liver as determined by Picro Sirius Red staining. d–g WT mice were placed on mMCD
for the duration of the study. After 1 week on mMCD diet (pre-treatment), mice were administered weekly i.v. dose of Invivofectamine-formulated siMCJ
(n= 6) or siRNAc (n= 6) for a total of 3 weeks and harvested 1 week after the last dose (4 weeks total on the diet). d Quantification of liver lipid content
by Sudan III staining of histological sections. e Quantification of liver inflammation by F4/80 immunostaining of histological sections. f Representative
images and (g) quantitation of liver fibrosis by Picro Sirius Red staining. h Quantification of 4-HNE staining of liver sections. *p < 0.05 siMCJ-treated
compared with PBS control by one-way ANOVA or Student’s t test analysis. Error bars show standard error (SE) in (d), (e), (g) and (h), and standard
deviation (SD) in (c). Source data are provided as a Source Data file.
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promotes the formation of supercomplexes that reduce electron
leak5–8,20. Under physiological conditions, MCJ deficient hepa-
tocytes have increased mitochondrial respiration but have no
elevated levels of ROS despite having an increased Complex I
activity6. We evaluated hepatic ROS in the mice on mMCD diet
by immunohistochemical staining for 4-hydoxynonenal (4-HNE),
an aldehyde product of lipid peroxidation used as a sensitive
marker of oxidative damage and lipid peroxidation21,22. The
levels of 4-HNE were not increased in siMCJ-treated mice groups
(Fig. 3h) demonstrating that hepatic ROS production is not
increased by MCJ silencing.
Correlating with the lower lipid accumulation, livers from
siMCJ-treated mice also had less hepatocyte damage as indicated
by reduced serum ALT levels (Supplementary Fig. 7d)
and diminished liver inflammation determined by the reduced
presence of F4/80-myeloid cells (Fig. 3e and Supplementary
Fig. 7e). Importantly, analysis of liver fibrosis, as a hallmark of
NASH, revealed markedly lower fibrosis in livers from siMCJ-
treated mice (Fig. 3f, g). Thus, treatment with siMCJ after the
onset of the disease prevented the development of liver fibrosis by
reducing lipid content in the liver.
Efficacy of LNP-siMCJ treatment in a metabolic disorder
model of NASH. Considering that NASH is frequently associated
with metabolic disorders such as obesity and diabetes, we inves-
tigated whether siMCJ treatment could be effective in the high
fat-high fructose diet (HF-HFD)23 model (resembling the Wes-
tern diet) where mice develop NASH. Mice were maintained on
this diet for 4 months prior to the initiation of the treatment. At
this time, the mice had already developed liver steatosis (Fig. 4a,
b, c) and fibrosis (Fig. 4d, e) and had an average weight of 50 g
(Fig. 4f). The mice were then treated with one dose of siMCJ per
week for a total of 5 weeks (5 doses total) and euthanized 1 week
after the last dose (5.5 months on the diet). The levels of MCJ in
the liver of siMCJ-treated mice remained low 1 week after the last
dose (Supplementary Fig. 8a). Liver steatosis was markedly
reduced in siMCJ-treated mice, as determined by H&E staining
(Fig. 4a and Supplementary Fig. 8b) as well as by lipid staining in
histological liver sections (Fig. 4b, c). In addition, liver fibrosis
was also reduced in siMCJ-treated mice as determined by the
number of fibrotic areas in the liver sections (Fig. 4d) as well as
the relative collagen area (Fig. 4e and Supplementary Fig. 8c).
Thus, treatment with siMCJ has efficacy in improving liver
steatosis and fibrosis in NASH under metabolic disorder
conditions.
Recent studies have suggested that the capacity of the liver to
metabolize fat could have an impact in the overall metabolism
and weight gain24. Blood glucose and serum insulin levels were
not affected by the treatment with siMCJ (Supplementary Fig. 8d,
e). However, while the weight of nontreated mice continued to
increase over the 6 weeks following the beginning of the
treatment, the weight of siMCJ-treated mice decreased (Fig. 4f).
To further support a potential benefit of disrupting MCJ in the
liver on metabolic disorders, we tested the effect of siMCJ in
weight gain in LepRdb mice, which show a continued increased
weight due to a genetic mutation in the leptin receptor leading to
a deficiency in leptin-mediated signaling25. Treatment started at
5 weeks of age and continued for 4 weeks. siMCJ also reduced
weight gain in this genetic mouse model (Supplementary Fig. 9).
Thus, reducing MCJ expression in the liver through the treatment
with siMCJ also contributes to minimize weight gain.
Insulin resistance and diabetes are also frequently found in
obese patients with NAFLD, although it is unclear whether this is
dependent on liver function or constitutes a comorbidity factor1,2.
We therefore tested whether silencing MCJ in the liver and
increasing hepatic mitochondrial function could affect insulin
resistance by treating mice on high fat diet for 13 weeks (known
to exhibit insulin resistance) with siMCJ. After 2 weeks of
treatment with siMCJ, an insulin tolerance test was performed by
determining blood glucose levels. siMCJ treatment increased
insulin response compared with control-treated mice (Supple-
mentary Fig. 10). These results show the efficacy of siMCJ as a
treatment for NASH in the context of obesity while managing
metabolic disorders.
To further demonstrate the effect of siMCJ treatment on liver
fibrosis we also examined its effect on aggressive liver fibrosis
caused by the administration of carbon tetrachloride (CCl4), the
most frequently used model to investigate liver fibrosis26. After
2 weeks of periodical i.p. injections of CCl4, mice were treated
weekly with siMCJ or vehicle control for 3 additional weeks (total
of 5 weeks with CCl4 administration). As reported, the levels of
serum ALT were only slightly elevated, and there was no
difference in the two groups (Supplementary Fig. 11a). Liver
fibrosis was evaluated by Picro Sirius Red staining of liver
sections. Unlike the diet models of NASH where fibrosis develops
mostly in perivenular area, mice treated with CCl4 develop a
pattern of fibrotic bridging between central and portal areas that
resembles that observed in advanced stage human NASH. As
previously described, after 2 weeks of CCl4 administration,
fibrosis was present but minimal signs of bridging could be found
(Supplementary Fig. 11b, c). After 5 weeks of CCl4 administra-
tions, marked bridging was present in mice from the control
group (Supplementary Fig. 11b, c). In contrast, while fibrosis was
present, fibrotic bridging was clearly reduced in the siMCJ-treated
mice (Supplementary Fig. 11b, c). Thus, treatment with siMCJ
after fibrosis is established reduces the progression to more
advance and detrimental stages of liver fibrosis.
siMCJ treatment lowers hepatocyte lipid levels by enhancing β-
oxidation. Although the initial causes of NAFLD remain unde-
fined, the pathological accumulation of lipids in the liver seems to
result from an imbalance between acquisition of lipids by de novo
lipogenesis or uptake, and catabolism of the lipids through β-
oxidation of fatty acids in mitochondria. The byproducts of β-
oxidation, NADH and FADH2, directly feed into the ETC to be
oxidized by Complex I and Complex II, respectively. Since MCJ is
a negative regulator of Complex I, removing this restraint on
Complex I activity could enhance the oxidation of NADH and
thereby enhance fatty acid β-oxidation. We first tested whether
silencing MCJ could increase mitochondrial respiration in the
fatty liver using the mMCD diet model. Mice were placed on
mMCD diet for 4 weeks and treatment with siMCJ started 1 week
after the initiation of the diet. Mitochondria were then isolated
from the livers of mMCD diet-fed mice and respiration in freshly
isolated mitochondria was examined using the Seahorse MitoS-
tress assay. The oxygen consumption rate (OCR) was elevated in
mitochondria from siMCJ-treated mice compared with non-
treated mice (Fig. 5a). Accordingly, mitochondrial ATP levels
were also increased in siMCJ-treated mice (Fig. 5b). Thus,
reducing MCJ in vivo by treatment with siMCJ in NAFLD
enhances mitochondrial respiration. We then tested whether
siMCJ treatment could also indirectly enhance fatty acid β-
oxidation in NAFLD. Using fresh liver sections from control and
siMCJ-treated mice on mMCD diet, analysis of fatty acid β-
oxidation by acid soluble metabolites (ASM) (Fig. 5c) and CO2
release (Fig. 5d) revealed a significant increase in β-oxidation in
the livers of siMCJ-treated mice. Consistent with these results, the
expression of genes involved in mitochondrial β-oxidation (Cpt1,
Acadm, Acadl, Fatp2, Abcd1, Pgc1α, and Nrf2) was also elevated
in the livers from siMCJ-treated mice (Fig. 5e). Thus, treatment of
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16991-2
6 NATURE COMMUNICATIONS |         (2020) 11:3360 | https://doi.org/10.1038/s41467-020-16991-2 | www.nature.com/naturecommunications
NAFLD with siMCJ enhances fatty acid β-oxidation in vivo. In
contrast, analysis of de novo lipogenesis using fresh liver sections
showed comparable levels of de novo synthesis free fatty acids,
diglycerides, and triglycerides in the liver between control and
siMCJ-treated mice (Fig. 5f). Moreover, the levels of TG in the
serum were low in both control and siMCJ-treated mice on
mMCD (Fig. 5g), indicating that the export of TG is not affected
by siMCJ treatment. Thus, siMCJ-treatment reduces liver lipid
accumulation in NAFLD by enhancing mitochondrial β-
oxidation and catabolism of the lipids.
Although excessive β-oxidation could lead to increased
production of ketone bodies, serum ketone bodies were not
elevated in siMCJ-treated mice relative to control mice on
mMCD diet (Fig. 5h). Since we have previously shown that the
loss of MCJ in deficient mice enhances TCA cycle activity as a
result of increased mitochondrial ETC activity5,7, the acetyl-CoA
generated during β-oxidation could be redirected to the TCA
cycle instead of the production of ketone bodies. Accordingly,
analysis of the TCA cycle enzyme malate dehydrogenase (MDH2)





















































































Fig. 4 siMCJ treatment decreases liver steatosis, fibrosis and weight gain in a NASH model with metabolic disorders. Mice were placed on a high-fat,
high-fructose diet (HF-HFD) for the duration of the study. Treatment with Invivofectamine-formulated siMCJ (n= 5) or PBS (n= 5) started after 4 months
on HF-HFD (pre-treatment) and was provided weekly for a total of 5 weeks. Tissues were harvest 1 week after the last treatment. a Quantification of liver
steatosis in H&E staining histological sections. b Representative images of liver lipids by Oil Red O staining. c Quantification of lipids from Oil Red O
stained-liver sections. d Number of fibrotic areas per histological section of the liver as determined by Picro Sirius Red staining. e Representative images of
Picro Sirius Red-stained liver sections. f Weight change after 6 weeks of treatment. *p < 0.05 siMCJ-treated compared with PBS control by one-way
ANOVA or Student´s t test analysis. Error bars show standard deviation (SD) in all panels. Source data are provided as a Source Data file.
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livers from siMCJ-treated mice compared with control mice on
mMCD diet (Fig. 5i). We also examined ROS production using
the glutathione (GSH) levels as a surrogate marker (low GSH
indicative of elevated oxidative stress since its antioxidant activity
is used to neutralize ROS). Interestingly, despite increased β-
oxidation and mitochondrial respiration, the levels of GSH in
livers from siMCJ-treated mice remained higher than in control
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Fig. 5 MCJ silencing enhances β-oxidation and prevents lipid accumulation in hepatocytes in vitro and in vivo. a–j Mice were placed on mMCD diet
1 week prior to the initiation of the treatment and maintained on the diet for the duration of the study. Treatment with Invivofectamine-formulated siMCJ
(n= 5) or siRNAc (n= 5) was given weekly for 3 weeks. Tissues were harvested 1 week after the last dose. a Oxygen consumption rate (OCR) using the
Seahorse analyzer. b ATP levels in isolated mitochondria. c Rate of fatty acid oxidation determined by the production of acid soluble metabolites (ASM).
d Rate of fatty acid oxidation determined by the production of CO2. e mRNA expression of fatty acid oxidation genes in siMCJ-treated liver relative to
control liver, as determined by real time RT-PCR. f De novo lipogenesis of fatty acids (FA), diglycerides (DG), and triglycerides (TG) in the liver.
g Triglycerides levels and (h) ketone bodies levels in serum. i Activity of malate dehydrogenase (MDH2) in liver extracts. j Glutathione (GSH) levels in
liver. k-l Primary hepatocytes from WT mice were transfected with siRNAc or siMCJ and were incubated with steatosis-inducing doses of oleic acid alone
for 24 h or in combination with rotenone for the last 6 h. k Representative images of lipid content and (l) quantification evaluated by Bodipy staining.
*denotes p < 0.05, as determined by Student’s t test analysis. Error bars show standard error (SE) in all the panels except panels (e) and (f) where error
bars show standard deviation (SD). Source data are provided as a Source Data file.
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approach to treat NAFLD as it prevents lipid accumulation by
boosting mitochondrial respiration and β-oxidation without
causing oxidative stress in the liver or ketosis.
To further demonstrate that the enhanced lipid catabolism in
the liver resulting from siMCJ-treatment is due to increased
Complex I activity in hepatocytes, we inhibited MCJ expression in
isolated primary hepatocytes from WT mice in vitro by
transfecting with siMCJ. siRNAc- and siMCJ-transfected hepato-
cytes were then incubated with a steatotic-dose of oleic acid in the
absence or presence of rotenone, a pharmacological inhibitor of
Complex I. Lipid content was quantified using BODIPY.
Consistent with the in vivo studies, attenuation of MCJ
expression prevented accumulation of lipids in hepatocytes
(Fig. 5k, l). However, inhibition of Complex I restored lipid
accumulation in the absence of MCJ (Fig. 5k, l). Thus, increasing
ETC activity through attenuation of MCJ expression is a unique
approach to accelerate lipid catabolism and prevent lipid
accumulation in the liver.
Therapeutic GalNAc-siMCJ reduces NASH liver steatosis and
fibrosis. Considering that hepatocytes are the preferential target
for LNP27 and that MCJ is more abundantly expressed in liver
hepatocytes relative to other liver resident cells6 (Supplementary
Fig. 1), silencing MCJ in hepatocytes is most likely the main
mechanism for the siMCJ/Invivofectamine effect in vivo. Never-
theless, to further verify the beneficial therapeutic effect of
silencing MCJ in hepatocytes, as an alternative to LNP, we
examined the use of N-Acetylgalactosamine (GalNAc) as a
delivery system for siRNA specifically to hepatocytes17,28,29.
GalNAc is the preferred method of siRNA delivery for treatment
of liver diseases that require extended periods of treatment and it
has been recently approved by the FDA as a delivery system for
siRNA in a liver rare disease. The major advantages of GalNAc as
a siRNA vehicle relative to LNP are its reduced immunogenicity,
its selectivity to hepatocytes (due to the expression of GalNAc
receptors), its s.c. administration (instead of i.v.), and its pro-
longed effect17,28,29. We therefore investigated the therapeutic
effect of GalNAc-siMCJ. Several stabilized siRNA sequences
specific for MCJ were conjugated to GalNAc, tested for their
capacity to silence MCJ gene expression in vitro and in vivo and
two GalNAc-siRNA sequences for MCJ (si381 and si393) were
selected for their superior efficacy in silencing MCJ gene
expression (Supplementary Fig. 12a). The efficacy of si381 and
si393 to lower MCJ protein levels in the liver was further con-
firmed by Western blot analysis (Fig. 6a). As expected, due to the
slower release of the GalNAc formulation, the kinetics of loss
were delayed relative to Invivofectamine, but by 3 days after s.c.
administration of si381, MCJ was undetectable in the liver
(Supplementary Fig. 12b). We first tested whether silencing MCJ
in hepatocytes with si381 and si393 had similar effect in reducing
lipid accumulation in the liver using the fasting model. After 36 h
of fasting, no MCJ could be detected in the livers from mice
treated with si381 or si393 (Supplementary Fig. 13a). There was
almost no detectable liver steatosis in mice treated with si381 or
si393 relative to mice treated with PBS, either by histological
analysis (Supplementary Fig. 13b, c) or by lipid staining in liver
sections (Fig. 6b and Supplementary Fig. 13d).
We also examined the efficacy of GalNAc-siMCJ in the MCD
diet model. Administration of si381 and si393 was initiated at the
time the mice were placed on the diet. A second dose was
provided 2 weeks later, and mice were harvested 1 week later. The
levels of MCJ in the liver remained markedly reduced in the
treated mice a week after the last treatment (Supplementary
Fig. 14a). Minimal lipid accumulation in the liver could be
detected in mice treated with si381 or si393, relative to control
mice (Fig. 6c, d). Importantly, treatment with si381 and
si393 suppressed the development of fibrosis (Fig. 6e and
Supplementary Fig. 14b).
To test the effect of a prolonged treatment with GalNAc-siMCJ
we used a choline-deficient high-fat diet (CD-HFD) model of
NAFLD. Mice were maintained in the diet for 4 months prior to
the initiation of the treatment, and were treated with si381 for
2 months with a dose every 2 weeks (total of 4 doses). The levels
of MCJ in the liver remained very low even 2 weeks after the last
dose of si381 (Supplementary Fig. 15a). Liver steatosis as
determined by H&E histological analysis was markedly reduced
in si381-treated mice relative to the control group (Fig. 6f and
Supplementary Fig. 15b). In addition, while extensive accumula-
tion of fat in the liver is achieved in this model, liver lipid content
was also highly reduced in mice treated with si381 (Fig. 4g and
Supplementary Fig. 15c).
To further test the efficacy of GalNAc-formulated MCJ siRNA
on the treatment of fibrosis in NASH after the onset of the
disease, we used the mMCD diet model. After 2 weeks on the
mMCD diet, mice had already developed significant steatosis as
determined by lipid accumulation in the liver (Fig. 6h and
Supplementary Fig. 16a) and histological analysis (Supplementary
Fig. 16b), as well as liver fibrosis (Fig. 4i). Mice were then treated
with si393 or PBS every 2 weeks for 4 additional weeks (2 doses).
Lipid accumulation (Fig. 6h and Supplementary Fig. 16a) and
overall histological liver steatosis (Supplementary Fig. 16b) were
markedly reduced in si393-treated mice compared with the
control group. In addition, while liver lipid content increased in
PBS-treated mice relative to the initiation of the treatment, no
difference was detected in si393-treated mice (Fig. 6h). Impor-
tantly, fibrosis analysis also revealed substantially lower levels of
liver fibrosis in si393-treated mice relative to the PBS-treated
group, as determined by Picro Sirius Red staining (Fig. 6i, j), as
well the levels of smooth muscle actin in liver (Fig. 6k). Similar to
lipid content, liver fibrosis in si393-treated mice was no different
from the levels of fibrosis at the initiation of the treatment (Fig. 6i,
k), indicating that treatment with GalNAc-siMCJ after develop-
ment of NASH prevents its progression. To address the safety of
the delivery of siMCJ with GalNAc, we also tested a single dose 3-
fold higher than the experimental dose of si393 under
physiological conditions for signs of toxicity. No signs of toxicity
could be observed 1 week (Supplementary Fig. 17) or 24 h
(Supplementary Fig. 18) after administration. Therefore, silencing
MCJ in hepatocytes through the delivery of GalNAc-siMCJ shows
safety and efficacy for the treatment of steatosis and fibrosis in
fatty liver disease.
Discussion
NAFLD is a complex disease with an alarming increasing inci-
dence around the world. In spite of numerous attempts, the
underlying molecular mechanisms responsible for NAFLD remain
largely unknown. Numerous pathogenic molecular pathways have
been described in the development and progression of NASH.
Some of the targets that have been pursued were initially identified
as targets for diabetes and other metabolic disorders (e.g., PPAR,
FGF-21)30,31. De novo lipid synthesis in the liver has been a fre-
quent pathway targeted with the goal of inhibiting and decreasing
the production of lipids (e.g., ACC)30,31. Blocking the release of
lipids from the adipose tissue to prevent their transport to the liver
is another approach that has been taken to clinical trials, but this
approach can result in weight gain30,31. Since fibrosis is the most
important predictor of overall and liver-related mortality, different
fibrotic targets as well as inflammation (the main trigger of
fibrosis) have been extensively explored (e.g., caspases, chemo-
kines, Galactin-3)30,31. Interestingly, boosting the catabolism of
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lipids in the liver mitochondria has received little attention.
However, the new thyroid receptor β-agonists, thought to enhance
fatty acid β-oxidation in mitochondria, are now in clinical trials as
treatment for fatty liver disease30,31. Here, we identify a pathway
that has not been targeted previously: enhancing mitochondrial
ETC activity in hepatocytes.
Two of the main products from fatty acid β-oxidation in the
mitochondria are NADH (the substrate reduced to NAD+ by
Complex I of the ETC) and FADH2 (substrate of Complex II of
the ETC) that feed into ETC. However, if the ETC activity is low,
the accumulation of NADH and FADH2 within the mitochondria
could provide a negative feedback to the β-oxidation process.
Thus, increasing Complex I activity and mitochondrial respira-
tion could indirectly enhance the catabolism of fatty acids
through fatty acid β-oxidation, but this approach has not been
obvious because there are not many known negative regulators of
the ETC to be targeted. We have previously identified MCJ as an
endogenous negative regulator of Complex I and mitochondrial
respiration in multiple cell types including hepatocytes5–7. In this
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expression in vivo enhances fatty acid β-oxidation in the liver in a
NASH model. In addition, we also show that the enhanced fatty
acid β-oxidation resulting from inhibiting MCJ is due to
enhanced Complex I activity. Thus, we identify an alternative
pathway to boost β-oxidation and lipid catabolism in the liver by
interfering with MCJ expression in hepatocytes.
While increasing fatty acid β-oxidation is a strategy to reduce
the accumulation of lipids in the liver and thereby reduce fibrosis,
increased β-oxidation is also known to cause increased ROS
production in the liver32–34 with potential toxic effects. Indeed,
treatment with thyroids and thyroid receptor β-agonists can
increase ROS levels in the liver, triggering mitophagy as a
mechanism to eliminate damaged mitochondria35. In contrast,
loss of MCJ increases Complex I activity and mitochondrial
respiration without increasing mitochondrial ROS production
because it also promotes the formation of respiratory complexes
(Complex I, III, and IV) in hepatocytes and other cells, and
thereby diminishes the risk of electron leak5–7. Here we show that
in vivo treatment of siMCJ of mice with NASH increases β-oxi-
dation, decreases lipid accumulation in the liver but does not
increase ROS production. The JNK pathway has been involved in
the initial mechanisms as well as in the progression of NAFLD36.
Mice lacking JNK1 and JNK2 are largely protected from liver
steatosis37,38. In addition, mitochondrial ROS are known to
activate the JNK pathway, which has been associated with
NAFLD36, but we have shown that loss of MCJ does not cause
activation of JNK in the liver6. Thus, unlike thyroid hormone
receptor agonists, targeting MCJ in the liver could provide a safer
therapeutic option since it prevents the generation of ROS.
Currently, all the therapeutic drugs undergoing clinical trials
for NASH are small molecules. Our data show, in contrast, that
the use of siRNA to reduce the levels of MCJ in the liver may
constitute an alternative therapeutic strategy16,17. Following the
initial excitement for the use of siRNA for therapeutic purposes,
the actual development of successful siRNA therapies has been a
long and complicated process. A critical challenge for the efficient
development of siRNA-based therapies has been the design of
delivery systems that specifically target the tissue of interest. In
spite of this, delivery to the liver has produced major success and
resulted in some FDA-approved drugs39. The most common
delivery system for siRNA to the liver has long been LNP and the
first LNP-formulated siRNA-based drug (Patisiran) was approved
in 2018 for the treatment of hATTR (hereditary transthyretin-
mediated) amyloidosis40. However, due to potential secondary
effects during prolonged treatments, particularly on the immune
system, GalNAc was developed as an alternative delivery system
for the liver that specifically targets hepatocytes28,29. GalNAc-
siRNA conjugates are synthesized by incorporating synthetic
triantennary GalNAc to a chemically modified siRNA. GalNAc is
specifically delivered to hepatocytes due to the presence of the
hepatocyte-specific asialoglycoprotein receptor28,29,41,42. Unlike
LNPs, GalNAc-siRNA conjugates can be delivered by sub-
cutaneous administration (s.c.), which can potentially allow for
self-administration. The first GalNAc-conjugated siRNA drug
(Givosiran) was FDA approved in 2019 for the treatment of acute
hepatic porphyria. There are over 30 clinical trials with different
GalNAc-conjugated siRNA to treat multiple clinical indications43.
Here we show that siMCJ formulated into LNP or GalNAc has
efficacy in reducing liver steatosis and fibrosis in multiple NASH
mouse models. To date no other siRNA-based drugs have been
tested in human clinical trials, therefore GalNAc-siMCJ could be
one of the first therapies tested in the future.
Overall, we show that liver-specific delivery systems for MCJ
safely reduce steatosis, inflammation, and fibrosis using different
mouse models of NAFLD. Thus, treatment with siMCJ could
emerge as a potential alternative therapeutic approach for this
disease.
Methods
Experimental procedures in animals. C57BL/6 J male mice were purchased from
Jackson Laboratory (Bar Harbor, ME) or bred at the AAALAC-accredited Uni-
versity of Vermont or CIC bioGUNE from breeding pairs obtained from Jackson
Laboratory. MCJ-deficient mice (MCJ KO) were already generated5. Leptin
receptor mutant (Leprdb/J) mice were obtained from Jackson Laboratories. The
studies were performed with male mice and experiments were initiated when the
mice were between 10 and 15 weeks of age. Animal procedures were approved by
the University of Vermont and University of Colorado Animal Care and Use
Committee according to the criteria outlined in the Guide for the Care and Use of
Laboratory Animals and institutional IACUC review committee. Animal work at
CIC bioGUNE was approved by the institutional IACUC and the Competent
Authority following Spanish and European regulations.
For fasting studies, all food was removed and tissues were harvested 36 h later.
For studies using the methionine and choline-deficient (MCD) diet model, mice
were fed a diet completely deficient in methionine and choline (MCD) (Research
Diets A02082002BRi) for either 2 or 3 weeks as indicated.
For studies using the modified methionine-,choline-deficient (mMCD) diet
model, mice were fed a choline-deficient diet containing 0.1% methionine with 45
kcal% fat (Research Diets, A06071309i) for 4 or 6 weeks.
For studies using the HF-HFD model, mice were fed a high fat/high fructose
diet consisting of a 58% fat diet with sucrose (Research Diets D12331i) in
combination with water containing 42 g/L of carbohydrate (55% fructose and 45%
sucrose)23. After 4 months on the diet, mice were treated weekly with siMCJ
formulated with Invivofectamine i.v. or PBS for 5 weeks.
For studies using the CD-HFD model, mice were fed a choline-deficient, high-
fat diet (45 kcal% fat, Research Diets, D05010402i) for 4 months prior to the
initiation of GalNAc-formulated siMCJ treatment. Mice then received s.c.
injections of 10 mg/Kg GalNAc siMCJ381or PBS every 2 weeks for a total of
4 doses.
For the studies using the diet induced obesity (DIO) mouse model and insulin
tolerance test (ITT), B6J DIO male mice were purchased from Jackson Laboratory
after 13 weeks in the D12492 high fat diet containing 60 kcal% fat. Mice were
maintained with the same diet during the treatment. Mice were treated weekly with
siMCJ formulated with Invivofectamine i.v. or PBS for only 2 weeks. Insulin
tolerance test was performed a week after the last dose of siMCJ. For ITT, blood
glucose was determined using a glucometer prior to the injection of insulin (time
0), following by the administration of insulin (0.75 mU/g) and determination of
Fig. 6 Treatment with GalNAc-siMCJ attenuates fatty liver disease. a Mice received a single s.c. dose of GalNAc-si381 (10mg/Kg), GalNAc-si393, or
PBS. MCJ expression in the liver was analyzed 5 days later by Western blot analysis. b Mice (n= 4) received a single dose of GalNAc-si381 or GalNAc-
si393 (10mg/Kg), or PBS. After 5 days they were fasted for 36 h. Liver lipids were quantified by Oil Red O staining. c–e Mice were administered with a s.c.
dose of GalNAc-si381 or GalNAc-si393 (n= 7), or PBS (n= 6) at the time they started on the MCD diet. A second dose was administered 2 weeks later.
Mice were harvested after 1 additional week. c Representative images of liver lipid accumulation by Oil Red O staining. d Quantitation of liver lipids.
e Quantitation of liver fibrosis by Picro Sirius Red staining. f and g Mice (n= 7) were fed choline-deficient high-fat diet (CD-HFD) for 4 months prior to the
treatment with a s.c. dose of GalNAc si381 or PBS every 2 weeks for 2 more months on the diet (4 doses total). Tissues were harvested 2-weeks after the
last dose. (f) Representative images of H&E stained-liver sections. (g) Quantification of liver lipids by Oil Red O staining. Percentage of total histological
area is shown. h–k After 2 weeks on mMCD diet (pre-treatment), mice (n= 5) received s.c. administration of GalNAc-si393 or PBS every 2 weeks for 4
additional weeks (2 doses total). Tissues were harvested 2 weeks after the last dose. h Quantitation of liver lipid by Oil Red O staining of liver sections.
i Quantitation of liver fibrosis by Picro Sirius Red staining (number of fibrotic areas per section). j Representative liver images of Picro Sirius Red staining.
k Relative expression of smooth muscle actin (Acta 2) mRNA levels by real-time RT-PCR and β2-microglobulin as house-keeping gene. *denotes p < 0.05,
as determined by one-way ANOVA or t test. Error bars show standard deviation (SD) in all panels. Source data are provided as a Source Data file.
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blood glucose after 15, 30, 60, and 90 min using the OneTouch Ultra glucometer
and glucose strips.
For the studies using the carbon tetrachloride (CCl4) model of liver fibrosis,
mice were administered i.p. 0.6 μl/g of CCl4 every 3 or 4 days. A group of mice were
harvested 2 weeks after the first CCl4 dose. After 2 weeks on CCl4, mice were
treated with invivofectamine/siMCJ (1.7 mg/Kg) or PBS control group weekly for 3
more weeks. Mice were then euthanized and tissues were harvested.
For treatment with siRNA in vivo, MCJ-specific siRNA (siMCJ) (position
294–312) was designed as previously described18. For in vivo delivery using
Invivofectamine, siMCJ was complexed with lipid nanoparticle Invivofectamine®
3.0 (ThermoFisher Scientific) according to the manufacturer’s instruction. Mice
received weekly i.v. injections of 1.7 mg/Kg of siRNA complexed with
invivofectamine. MCJ-specific siRNAs formulated with GalNAc were provided by
Alnylam Pharmaceuticals, Inc. GalNAc-siRNAs targeting MCJ were selected using
in vitro cell-based activity screens in primary mouse hepatocytes with confirmation
of activity in WT mice. The two selected siRNAs (si381 and si393) were conjugated
to an N-Acetylgalactosamine (GalNAc) for optimized delivery in hepatocytes as
previously described44. The siRNA duplexes targeting mouse MCJ (Dnajc15) were
designed to maximize predicted efficacy and minimize off-target effects using
proprietary algorithms (Alnylam). For in vivo screening, mice received a 10 mg/Kg
s.c. dose in PBS of different MCJ-specific GalNAc-siRNA selected from the in vitro
screening. After 2 weeks, liver expression of DnaJC15 was measured by Taqman
RT-PCR using the following assay from ThermoFisher (Mm00481271_m1).
GalNAc-si381 or GalNAc-si393 were selected from the in vivo studies and used for
treatment of mice on the different diets at 10 mg/Kg in PBS administered s.c. every
2 weeks. Fully chemically-modified GalNAc-siRNA conjugates were employed to
confer drug-like properties (Pharmacokinetics, pharmacodynamics, safety). Pattern
of 2′-fluoro and 2′-O-methyl modifications were employed to improve in vivo
potency45. si381 and si393 antisense strands target the following nucleotide
sequence of the mouse MCJ transcript (NM_025384.3), respectively (404–424 and
358–378).
Human samples. Healthy human liver (n= 5) samples from Valdecilla Hospital
(Santander, Spain) were used as controls. All had histologically healthy liver, BMI
<25 Kg/m2, normal fasting glucose, cholesterol and TG, normal AST and ALT, and
no evidence of viral infections (HBV, HCV, and HIV). Diseased liver samples come
from 21 patients with a clinical diagnosis of NAFLD who underwent a liver biopsy
with diagnostic purposes in Santa Cristina Hospital (Madrid, Spain). Inclusion
criteria for NAFLD patients were based on an alcohol intake lesser than 20 g/day,
the presence of biopsy-proven steatosis with/without necroinflammation and/or
fibrosis, and no evidence of hepatitis B and/or C virus (HBV and/or HCV,
respectively) infection as well as human immunodeficiency virus (HIV) infection.
The characteristics of the study groups are described in Table 1. Clinical exam-
ination included a detailed interview with special emphasis on both alcohol intake
and medications use, history of known diabetes and arterial hypertension, as well as
measurements of weight, height, blood pressure, and waist and hip perimeters.
Body mass index (BMI) was calculated as weight (Kg) divided by height (m)
squared. Fasting blood samples were obtained and used to measure alanine and
aspartate transaminases (ALT and AST, respectively), GGT, total cholesterol, HDL-
cholesterol, triglyceride, glucose, HbA1c, and insulin. Insulin resistance was cal-
culated using the homeostatic model assessment (HOMA-IR) index1. Hepatic
histopathological analysis was performed according to the scoring system of
Kleiner et al.2. Four histopathological features were semi-quantitatively evaluated:
grade of steatosis (0, <5%; 1, 5%–30%; 2, >30–60%; 3, >60%), lobular inflammation
(0, no inflammatory foci; 1, <2 inflammatory foci per 200x field; 2, 2–4 inflam-
matory foci per 200x field; 3, >4 inflammatory foci per 200x field), hepatocellular
ballooning (0, none; 1, few balloon cells; 2, many cells/prominent ballooning), and
stage of fibrosis (from 0, none to 4, cirrhosis). Simple steatosis was defined as the
presence of at least 5% of steatotic hepatocytes with or without mild lobular or
portal inflammation but in the absence of features of hepatocellular injury (bal-
looning, apoptosis, or necrosis) and fibrosis. On the other hand, minimal criteria
for the histological diagnosis of definite NASH included the combined presence of
grade 1 steatosis, hepatocellular injury, and lobular inflammation with or without
fibrosis. The study was performed in agreement with the Declaration of Helsinki,
and with local and national laws. The Human Ethics Committee of Santa Cristina
Hospital, the Comité Consultatif de Protection des Personnes dans la Recherche
Biomédicale de Nice or the Human Ethics Committee of Valdecilla Hospital
approved the study procedures, and written informed consent was obtained from
all patients before inclusion in the study.
Histology. To perform H&E and Picro Sirius Red staining, paraffin-embedded
liver samples were sectioned, dewaxed with a xylene substitute (HS-202, Histoclear;
National Diagnostics, Atlanta, GA), and hydrated. Sections were stained for 5 min
with Harry’s hematoxylin (HHS128-4L; Sigma) and for 15 min with aqueous eosin
(HT110232-1L; Sigma) for H&E staining or with 0.01% Fast green FCF in saturated
picric acid for 15 min and 0.04% Fast green For Coloring Food/0.1% Sirius red in
saturated picric acid for 15 min for Sirius red staining. Samples were dehydrated
and cleared with Histoclear. Finally, sections were mounted in DPX mounting
media (06522, 500 mL; Sigma).
To perform Sudan III staining ornithine carbamyl transferase–embedded frozen
samples were sectioned, cleared with 60% isopropanol, and stained with Sudan III
solution (0.5% in isopropanol Sudan III Panreac) for 1 h and finally cleared with
60% isopropanol. Sections were counterstained with Mayer hematoxylin (MHS32-
1L; Sigma) and mounted in aqueous mounting medium for lipid quantification.
To perform Oil Red O staining tissue sections from frozen tissue were stained
with 0.2% Oil Red O and counterstained with hematoxylin.
To perform immunostaining in liver section, F4/80 samples were unmasked
with proteinase K during 15 min at room temperature and MCJ samples with
citrate buffer pH 6.0 during 20 min at 97 °C. Endogenous peroxidase activity was
blocked for 10 min with 3% hydrogen peroxide, then sections were blocked with
5% normal goat serum for 30 min and incubated with F4/80 (1:50, 1 h at 37 °C,
MCA497BB; Bio-Rad, Hercules, CA) or MCJ (B0027R BioMosaics) (1.100,
overnight at 4 °C) followed by 30 min with anti-rat or anti-mouse reagents.
Colorimetric detection was completed with Vector Vip purple substrate (sk-4600;
Vector). Slides were counterstained with Mayer Hematoxylin (MHS32-1L; Sigma),
and finally samples were dehydrated, cleared, and mounted in DPX mounting
media (06522-500 mL; Sigma).
For the analysis, images from liver sections stained H&E, Picro Sirius Red,
Sudam III, or Oil Red Oil were taken with an upright light microscope (Zeiss,
Germany), or slides were scanned using the Leica-Aperio Versa (University of
Vermont Imaging Facility). The average sum of intensities and stained area
percentage of each sample was calculated using FRIDA software (http://bui3.win.
ad.jhu.edu/frida/, John Hopkins University). No manipulation of the histological
microscopy images was performed.
De novo lipogenesis analysis in liver. De novo lipogenesis was performed as
previously described3 with slight modifications. In brief, freshly isolated tissue
slices (40 mg) were incubated in high glucose DMEM with insulin (150 nM) and
[H3] Acetic acid 20 µCi/ml for 4 h. Tissue slices were washed five times in cold PBS,
homogenized in PBS and lipids were extracted and separated by TLC4,5, each lipid
was scraped and the radioactivity was measured in a scintillation counter.
β-oxidation analysis. Beta oxidation was assessed as follows6,7. Fresh liver pieces
were homogenized using a Potter homogenizer (5 strokes) in cold buffer (25 mM
Tris-HCl, 500 nM sucrose, 1 mM EDTA-Na2 pH 7,4) and sonicated for 10 s. Then,
the homogenates were centrifuged at 500 × g for 10 min at 4 °C. Approximately
500 µg of protein from the homogenate supernatants was used for the assay in a
volume of 200 µl. The reaction started by adding 400 µl of assay mixture containing
0.5 µCi/ml [1-14C] palmitic acid to the samples and was incubated for 1 h at 37 °C
in microfuge tubes with a Whatman paper circle in the cap. The reaction was
stopped by adding 300 µl of 3 M perchloric acid and 1M NaOH was added to
impregnate the Whatman cap. After 2 hours the Whatman caps were retired and
the radioactivity associated was measured in a scintillation counter. The microfuge
tubes were centrifugated at 21,000 × g for 10 min at 4 °C. 400 µl of the supernatants
were collected and the radioactivity was counted in a scintillation counter. The
supernatant contained the ASM and the Whatman caps captured the released CO2.
Serum analysis. Serum TGA were measured using a commercially available kit
Triglycerides Liquid Mono (Krotest Laboratorios). Serum ketone bodies were
measured using a commercially available kit from Wako Chemicals (Richmond,
Table 1 Characterization of NAFLD patients.
NAFLD patients
Number of patients 21
Age (years) 50.2 ± 15.2
BMI (kg/m²) 29.6 ± 3.9
Obesity, n (%) 7 [33.3%]
Gender (Female/Male) 17/4
ALT (IU/L) 24.2 ± 16.8
AST (IU/L) 20.4 ± 7.6
GGT (IU/L) 49.9 ± 50.2
HOMA-IR 2.7 ± 1.9
Insulin resistance, n (%) 11 [52.4%]
Total cholesterol (mg/dl) 212 ± 46.1
HDL-cholesterol (mg/dl) 48.4 ± 16.2
Triglyceride (mg/dl) 159.5 ± 72.3
Liver steatosis grade: 0/1/2/3 (n) 0/15/5/1
NASH, n (%) 3 [14.3%]
Grade of liver fibrosis: 0/1/2/3/4 (n) 19/2/0/0/0
BMI body mass index, ALT alanine aminotransferase, AST aspartate amino transferase, GGT
gamma glutamyl transferase, HOMA-IR homeostatic model assessment of Insulin resistance,
HDL high density lipoprotein, NASH non-alcoholic steatohepatitis.
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VA). Serum albumin and urea were measured using BioVision’s Albumin Assay
Kit and Urea Assay Kit II, respectively (Milpitas, CA). Aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) were measured by multiple-point rate
reflectance spectrophotometry on a Orhto Vitros 5600 analyzer. Serum insulin
levels were determined using the Insulin (Mouse) ELISA kit (BioVision).
Isolation and culture of primary hepatocytes. Primary hepatocytes were isolated
from male C57BL/6 WT mice via collagenase perfusion8. For in vitro silencing, WT
primary hepatocytes were transfected with 100 nM MCJ siRNA using Jetprime
reagent (Polyplus). Controls were transfected with an unrelated siRNA (Qiagen).
For BODIPY staining, primary hepatocytes were incubated with 400 μM oleic acid
and the complex I inhibitor Rotenone (Sigma-Aldrich) (1 μM) for the indicated
times. Hepatocytes in culture were incubated with BODIPY 493/503 (Molecular
Probes) at 1 mg/ml during 30 min prior to fixation (4% paraformaldehyde). Ima-
ging was performed with an Axioimager D1 microscope and quantification of lipid
bodies was performed using Frida Software.
Western blot analysis. Total protein and mitochondrial fraction protein from
primary hepatocytes and liver tissue were resolved on sodium dodecyl sulfate-
polyacrylamide gels and transferred to nitrocellulose or polyvinylidene difluoride
(PVDF) membranes. Membranes were incubated with anti-mouse MCJ9 or anti-
mouse GAPDH (Santa Cruz, Abcam) overnight. Primary antibodies were detected
with anti-rabbit-IgG-HRP (Cell Signaling, Jackson Laboratory) and anti-mouse
IgG-HRP (Santa Cruz Biotechnology) and signal developed with chemilumines-
cence (KPL) on an Amersham Imager 600.
RNA isolation and quantitative real-time polymerase chain reaction (RT-
PCR). Total RNA was isolated with Trizol (Invitrogen). Total RNA (1–2 μg) was
treated with DNase (Invitrogen) and reverse transcribed into cDNA using M-MLV
Reverse Transcriptase (Invitrogen). Quantitative real -time PCR (RT-PCR) was
performed using SYBR® Select Master Mix (Applied Biosystems) and the Viia 7
Real-Time RT-PCR System (Applied Biosystems). The Ct values were extrapolated
to a standard curve, and data was then normalized to the house-keeping expression
(GAPDH). For real time RT-PCR of Acta2, we used the assay on demand primers
and probe #Mm00725412 from ThermoFisher. Primers used for the rest of the
other analyses are shown in Supplementary Table 1.
Mitochondrial respiration analysis. Liver mitochondrial respiration was mea-
sured at 37 °C by high-resolution respirometry using the Seahorse Bioscience
XF24-3 Extracellular Flux Analyzer. For the measurement of the OCR, as the rate
change of dissolved O2, liver mitochondria were isolated and plated in a XF24 cell
culture microplate (Seahorse Bioscience), 5 μg per well as indicated10. Mitochon-
dria were incubated in a media containing substrates for both complexes I and II:
Glutamate (10 mM), Malate (2 mM), and Succinate (10 mM). After an OCR
baseline measurement, sequential injections through ports in the XF Assay car-
tridges of pharmacologic inhibitors: ADP (4 mM) (state 3 respiration), Oligomycin
(3 μM), an inhibitor of ATP synthase, which allows a measurement of ATP-
coupled oxygen consumption through oxidative phosphorylation (OXPHOS);
carbonyl cyanide 4-trifluoromethoxy-phenylhydrazone (FCCP) (4 μM), an
uncoupling agent that allows maximum electron transport, and therefore a mea-
surement of maximum OXPHOS respiration capacity; and finally Antimycin A
(4 μM)+ Rotenone (2 μM), mitochondrial complex I and III inhibitors respec-
tively, were performed and changes in OCR were analyzed. The normalized data
were expressed as pmol of O2 per minute or milli-pH units (mpH) per minute, per
viability measured by MTT assay.
MDH2 activity. MDH2 activity was measured in liver extracts using the recom-
mendation from the kit from Abcam ab119693.
ATP level determination. The levels of ATP in liver mitochondria were deter-
mined using the ATPlite luminescence ATP detection assay system (PerkinElmer)
by following the recommendations from the manufacturer. Mitochondrial fractions
were obtained using the Mitochondrial Fractionation Kit (ActiveMotif) for hepatic
tissue.
ROS production analysis. For GSH quantification, liver extracts were analyzed
with a UPLC system (Acquity, Waters, Manchester) coupled to a Time of Flight
mass spectrometer (ToF MS, SYNAPT G2, Waters). A 2.1 × 100 mm, 1.7 μm BEH
amide column (Waters), thermostated at 40 °C, was used to separate the analytes
before entering the MS. Solvent A (aqueous phase) consisted of 99.5% water, 0.5%
formic acid, and 20 mM ammonium formate while solvent B (organic phase)
consisted of 29.5% water, 70% MeCN, 0.5% formic acid, and 1 mM ammonium
formate. The extracted ion trace was obtained for GSH (m/z= 308.0916) in a
20 mDa window and subsequently smoothed (2 points, 2 iterations) and integrated
with QuanLynx software (Waters, Manchester). Concentrations were converted
into amount of analyte per mg liver tissue.
To evaluate lipid peroxidation in liver as marker of oxidative stress21,22, liver
sections were immunostained for 4-HNE (Abcam, UK) as recommended by the
manufacturer (Abcam). Immunostained images were visualized on an Axioimager
D1 microscope, and the results were analyzed using the Frida software.
Statistical analysis. Statistical significance was determined by one-way analysis of
variance or Student’s t test analysis, otherwise specified. All error bars represent
standard deviation (SD), except when specified.
Comparison of DNAJC15 promoter CpG methylation with gene expression.
DNA methylation IDAT files for 50 TCGA healthy liver samples46 were
downloaded from the Genomic Data Commons (gdc.cancer.gov) and pre-
processed using in-house pipelines. The pre-processing/filtering procedure left
451,561 CpGs in 47 noncancer liver tissues. The data set was further restricted to
40 subjects with matched RNA-seq data. The relation of the 3 DNAJC15 CpGs
(cg14729962, cg09677945, cg15988970) and gene expression was determined by
linear regression implemented in R version 3.5.1.
Comparison of DNAJC15 methylation in NAFLD to normal human liver. MCJ/
DnaJC15 DNA methylation profiles from NAFLD patients and healthy human
liver were publicly available in six GEO, (www.ncbi.nlm.nih.gov/geo) data sets
listed in Table 2.
Two-tailed Wilcoxon’s rank sum tests were used to compare methylation of the
three CpGs of interest (cg14729962, cg09677945, cg15988970)15 between liver
tissue of NAFLD and healthy subjects. The total sample sizes for statistical
comparisons were: 193, 190, and 141 for each of the above CpGs listed; cg09677945
was missing in GSE69852 (n= 3 healthy), and cg15988970 was missing in
GSE61278 (n= 52 healthy). All statistical analysis and data visualization were
performed in R version 3.5.1.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all the data supporting the findings of this study are available
within the paper and its supplementary information files. The publicly available datasets
analyzed to assess DNAJC15 methylation profiles during the current study are available
in the Gene Expression Omnibus repository with the accession codes GSE48325,
GSE49542, GSE61258, GSE61278, GSE65057, and GSE69852. Source data are provided
with this paper.
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